Anlotinib potentiates anti-PD1 immunotherapy via transferrin receptor-dependent CD8⁺ T-cell infiltration in hepatocellular carcinoma

Abstract

	•Synergistic effects of anlotinib and anti-PD-1 immunotherapy demonstrated in HCC preclinical models.
	•Anlotinib inhibits TFRC expression via the VEGFR2/AKT/HIF-1α pathway.
	•CXCL14 upregulation via TFRC suppression boosts CD8+ T-cell recruitment.
	•TFRC emerges as a potential biomarker for evaluating prognosis and predicting response to anti-PD-1-based therapies in advanced HCC patients.

Keywords

hepatocellular carcinoma / immune checkpoint blockade / transferrin receptor / tumour microenvironment / tyrosine kinase inhibitor

References

[1] HeX, XuC. Immune checkpoint signaling and cancer immunotherapy. Cell Res. 2020;30:660-669.

[2] MintonK. Immune checkpoint blockade breaches the mucosal firewall to induce gut microbiota translocation. Nat Rev Immunol. 2023;23:269.

[3] LlovetJM, KelleyRK, VillanuevaA, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7:6.

[4] Meric-BernstamF, LarkinJ, TaberneroJ, Bonini C. Enhancing anti-tumour efficacy with immunotherapy combinations. Lancet. 2021;397:1010-1022.

[5] YauT, KangYK, KimTY, et al. Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: the CheckMate 040 randomized clinical trial. JAMA Oncol. 2020;6:e204564.

[6] ZhuXD, SunHC. Emerging agents and regimens for hepatocellular carcinoma. J Hematol Oncol. 2019;12:110.

[7] FinnRS, RyooBY, MerleP, et al. Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial. J Clin Oncol. 2020;38:193-202.

[8] ChuY, DaiE, LiY, et al. Pan-cancer T cell atlas links a cellular stress response state to immunotherapy resistance. Nat Med. 2023;29:1550-1562.

[9] MoradG, Helmink BA, SharmaP, WargoJA. Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. Cell. 2021;184:5309-5337.

[10] YiC, ChenL, LinZ, et al. Lenvatinib targets FGF receptor 4 to enhance antitumor immune response of anti-programmed cell death-1 in HCC. Hepatology. 2021;74:2544-2560.

[11] ShenG, ZhengF, RenD, et al. Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development. J Hematol Oncol. 2018;11:120.

[12] SuY, LuoB, LuY, et al. Anlotinib induces a T cell-inflamed tumor microenvironment by facilitating vessel normalization and enhances the efficacy of pd-1 checkpoint blockade in neuroblastoma. Clin Cancer Res. 2022;30:793-809.

[13] XuQ, WangJ, SunY, et al. Efficacy and safety of sintilimab plus anlotinib for PD-L1-positive recurrent or metastatic cervical cancer: a multicenter, single-arm, prospective phase II trial. J Clin Oncol. 2022;40:1795-1805.

[14] ChuT, ZhongR, ZhongH, et al. Phase 1b study of sintilimab plus anlotinib as first-line therapy in patients with advanced NSCLC. J Thorac Oncol. 2021;16:643-652.

[15] YangXR, XuY, YuB, et al. High expression levels of putative hepatic stem/progenitor cell biomarkers related to tumour angiogenesis and poor prognosis of hepatocellular carcinoma. Gut. 2010;59:953-962.

[16] LlovetJM, Lencioni R. mRECIST for HCC: performance and novel refinements. J Hepatol. 2020;72:288-306.

[17] CañadasI, Thummalapalli R, KimJW, et al. Tumor innate immunity primed by specific interferon-stimulated endogenous retroviruses. Nat Med. 2018;24:1143-1150.

[18] JenkinsRW, ArefAR, LizottePH, et al. Ex vivo profiling of PD-1 blockade using organotypic tumor spheroids. Cancer Discov. 2018;8:196-215.

[19] SunHX, XuY, YangXR, et al. Hypoxia inducible factor 2 alpha inhibits hepatocellular carcinoma growth through the transcription factor dimerization partner 3/E2F transcription factor 1-dependent apoptotic pathway. Hepatology. 2013;57:1088-1097.

[20] ChouTC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev. 2006;58:621-681.

[21] ChenX, LiW, WuX, et al. Safety and efficacy of sintilimab and anlotinib as first line treatment for advanced hepatocellular carcinoma (KEEP-G04):a single-arm phase 2 study. Front Oncol. 2022;12:909035.

[22] HuB, XuY, LiYC, et al. CD13 promotes hepatocellular carcinogenesis and sorafenib resistance by activating HDAC5-LSD1-NF-kappaB oncogenic signaling. Clin Transl Med. 2020;10:e233.

[23] GaoJ, ShiLZ, ZhaoH, et al. Loss of IFN-γ pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy. Cell. 2016;167:397-404.

[24] CoelhoMA, CooperS, StraussME, et al. Base editing screens map mutations affecting interferon-gamma signaling in cancer. Cancer Cell. 2023;41:288-303.

[25] QiD, LuM, XuP, et al. Transcription factor ETV4 promotes the development of hepatocellular carcinoma by driving hepatic TNF-alpha signaling. Cancer Commun (Lond). 2023;43:1354-1372.

[26] KimH, Villareal LB, LiuZ, et al. Transferrin receptor-mediated iron uptake promotes colon tumorigenesis. Adv Sci (Weinh). 2023;10:e2207693.

[27] XiaoX, Moschetta GA, XuY, et al. Regulation of iron homeostasis by hepatocyte TfR1 requires HFE and contributes to hepcidin suppression in beta-thalassemia. Blood. 2023;141:422-432.

[28] ChengAL, HsuC, ChanSL, Choo SP, KudoM. Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma. J Hepatol. 2020;72:307-319.

[29] ClucasJ, MeierP. Roles of RIPK1 as a stress sentinel coordinating cell survival and immunogenic cell death. Nat Rev Mol Cell Biol. 2023;24:835-852.

[30] GalluzziL, VitaleI, WarrenS, et al. Consensus guidelines for the definition, detection and interpretation of immunogenic cell death. J Immunother Cancer. 2020;8:e000337.

[31] SongF, HuB, ChengJW, et al. Anlotinib suppresses tumor progression via blocking the VEGFR2/PI3K/AKT cascade in intrahepatic cholangiocarcinoma. Cell Death Dis. 2020;11:573.

[32] HouS, Clement RL, DialloA, et al. FoxP3 and Ezh2 regulate Tfr cell suppressive function and transcriptional program. J Exp Med. 2019;216:605-620.

[33] WangJ, YuX, GongW, et al. EZH2 noncanonically binds cMyc and p300 through a cryptic transactivation domain to mediate gene activation and promote oncogenesis. Nat Cell Biol. 2022;24:384-399.

[34] WestrichJA, Vermeer DW, SilvaA, et al. CXCL14 suppresses human papillomavirus-associated head and neck cancer through antigen-specific CD8(+) T-cell responses by upregulating MHC-I expression. Oncogene. 2019;38:7166-7180.

[35] KumarA, Mohamed E, TongS, et al. CXCL14 promotes a robust brain tumor-associated immune response in glioma. Clin Cancer Res. 2022;28:2898-2910.

[36] DolinskaM, CaiH, ManssonA, et al. Characterization of the bone marrow niche in patients with chronic myeloid leukemia identifies CXCL14 as a new therapeutic option. Blood. 2023;142:73-89.

[37] HuB, LiH, GuoW, et al. Establishment of a hepatocellular carcinoma patient-derived xenograft platform and its application in biomarker identification. Int J Cancer. 2020;146:1606-1617.

RIGHTS & PERMISSIONS

2024 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.